Reference priceEUR €4.95Original source price: INR 450.00. Converted estimates are available by currency selection.
| Brand | Opzelura topical |
|---|---|
| Manufacturer | Incyte Corporation |
| Prescription required | Yes |
Opzelura topical 1.5% Cream 1tubes x 100g(ruxolitinib)
ruxolitinib
Description
Opzelura topical 1.5% Cream 1tubes x 100g(ruxolitinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: ruxolitinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Incyte Corporation. Therapeutic category: Medicine Library > Dermatology Medicines > Vitiligo medicine. Pack information: 100. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
OPZELURA is a Janus kinase (JAK) inhibitor indicated for: Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.How to Use
Use ruxolitinib under the supervision of a qualified healthcare professional. Apply it only to the intended area as directed. Avoid eyes, mucous membranes, or broken skin unless the approved label specifically instructs otherwise. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: ruxolitinib. Pack size: 100. Pack unit: unit. Manufacturer: Incyte Corporation. Origin country: United States. Source category: Medicine Library > Dermatology Medicines > Vitiligo medicine. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.